Literature DB >> 1854170

Liposomal amphotericin B inhibits in vitro T-lymphocyte response to antigen.

J M Boggs1, N H Chang, A Goundalkar.   

Abstract

The effects of free amphotericin B (as Fungizone) and amphotericin B (AMB) incorporated into liposomes on the proliferation of lymphocytes were determined. Freshly obtained guinea pig and rat antigen-specific lymphocytes were compared with rat T-lymphocyte cell lines cultured for a long period of time. Incorporation of AMB into multilayered vesicles significantly reduced its effect relative to that of Fungizone on cultured T-cell lines, as reported by others for mammalian cells. In contrast, the effects on freshly obtained antigen-specific lymphocytes were different. Fungizone inhibited proliferation of antigen-specific lymph node cells freshly obtained from immunized guinea pigs at fungicidal concentrations, and incorporation into multilayered lipid vesicles did not have much of a protective effect. Higher concentrations of Fungizone were required to inhibit proliferation of fresh rat lymph node cells, but incorporation into multilayered lipid vesicles still did not have much of a protective effect. Some T lymphocytes in the peripheral circulation of guinea pigs and in the lymph nodes of rats were more resistant to liposomal AMB than another more sensitive T-lymphocyte population was. Proliferation of lymphocytes in response to mitogens was inhibited less than that in response to specific antigen was. Thus, sensitivity to AMB depended on the species, the strength of the stimulus used to activate the lymphocytes, and on some other property of the lymphocytes, possibly their state of differentiation. Regardless of the reason for the difference in effects on freshly obtained lymph node lymphocytes and cultured line cells, the former may be more relevant to effects in vivo and should be considered in a complete evaluation of the in vivo toxicity of these forms of the drug. Incorporation into sonicated unilamellar vesicles had more of a protective effect, while equimolar drug-lipid complexes had even more of a protective effect. These forms of AMB might have less of an immunosuppressive potential than multilayered vesicles containing low amounts of AMB do.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1854170      PMCID: PMC245123          DOI: 10.1128/AAC.35.5.879

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Effect of amphotericin B and clotrimazole on lymphocyte stimulation.

Authors:  A Tärnvik; S Ansehn
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

2.  Effect of bovine basic protein charge microheterogeneity on protein-induced aggregation of unilamellar vesicles containing a mixture of acidic and neutral phospholipids.

Authors:  S Cheifetz; M A Moscarello
Journal:  Biochemistry       Date:  1985-04-09       Impact factor: 3.162

Review 3.  Liposomes as drug delivery system in the treatment of infectious diseases. Potential applications and clinical experience.

Authors:  A Coune
Journal:  Infection       Date:  1988 May-Jun       Impact factor: 3.553

4.  Effect of liposomal amphotericin B on murine macrophages and lymphocytes.

Authors:  R T Mehta; K Mehta; G Lopez-Berestein; R L Juliano
Journal:  Infect Immun       Date:  1985-02       Impact factor: 3.441

5.  Antigen-targeted liposome-encapsulated methotrexate specifically kills lymphocytes sensitized to the nonapeptide of myelin basic protein.

Authors:  J M Boggs; A Goundalkar; F Doganoglu; N Samji; J Kurantsin-Mills; K M Koshy
Journal:  J Neuroimmunol       Date:  1987-12       Impact factor: 3.478

6.  Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study.

Authors:  G Lopez-Berestein; V Fainstein; R Hopfer; K Mehta; M P Sullivan; M Keating; M G Rosenblum; R Mehta; M Luna; E M Hersh
Journal:  J Infect Dis       Date:  1985-04       Impact factor: 5.226

7.  Lymphocyte plasma membranes. III. Composition of lymphocyte plasma membranes from normal and immunized rats.

Authors:  W I Smith; C T Ladoulis; D N Misra; T J Gill; H Bazin
Journal:  Biochim Biophys Acta       Date:  1975-04-08

8.  Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.

Authors:  R L Juliano; C W Grant; K R Barber; M A Kalp
Journal:  Mol Pharmacol       Date:  1987-01       Impact factor: 4.436

9.  Design of liposomes to improve delivery of amphotericin-B in the treatment of aspergillosis.

Authors:  I Ahmad; A K Sarkar; B K Bachhawat
Journal:  Mol Cell Biochem       Date:  1989 Nov 23-Dec 19       Impact factor: 3.396

10.  Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

Authors:  F C Szoka; D Milholland; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

View more
  5 in total

1.  Influence of liposomal amphotericin B on CD8 T-cell function.

Authors:  M Kretschmar; G Geginat; T Bertsch; S Walter; H Hof; T Nichterlein
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 2.  In vitro models for studying toxicity of antifungal agents.

Authors:  V Joly; J Bolard; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

Review 3.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

4.  Hemophagocytic lymphohistiocytosis associated with visceral leishmaniasis in late adulthood.

Authors:  Guilherme Grossi Lopes Cançado; Guilherme Gomes Freitas; Flavia Helena Fidelis Faria; Antonio Vaz de Macedo; Vandack Nobre
Journal:  Am J Trop Med Hyg       Date:  2013-01-16       Impact factor: 2.345

5.  Impact of Antifungal Compounds on Viability and Anti-Aspergillus Activity of Human Natural Killer Cells.

Authors:  Stanislaw Schmidt; Ralf Schubert; Lars Tramsen; Thomas Lehrnbecher
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.